These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 20646933)

  • 1. Ulinastatin-mediated protection against zymosan-induced multiple organ dysfunction in rats.
    Yang Q; Liu X; Liu M; Zhang L; Guan Y
    Biologicals; 2010 Sep; 38(5):552-6. PubMed ID: 20646933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olprinone, a specific phosphodiesterase (PDE)-III inhibitor, reduces the development of multiple organ dysfunction syndrome in mice.
    Mazzon E; Esposito E; Di Paola R; Impellizzeri D; Bramanti P; Cuzzocrea S
    Pharmacol Res; 2011 Jul; 64(1):68-79. PubMed ID: 21193041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of elderly and adult multiple organ dysfunction syndrome in the rat model.
    Zhu Q; Qian X; Wang S; Yin T; Yang J; Xue Q; Xu B
    Exp Gerontol; 2006 Aug; 41(8):771-7. PubMed ID: 16797904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 10 mitigates the development of the zymosan-induced multiple organ dysfunction syndrome in mice.
    Jansen MJ; Hendriks T; de Man BM; van der Meer JW; Goris RJ
    Cytokine; 1999 Sep; 11(9):713-21. PubMed ID: 10479408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical study on effects of ulinastatin on patients with systemic inflammatory response syndrome].
    Shao YM; Zhang LQ; Deng LH; Yao HG
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2005 Apr; 17(4):228-30. PubMed ID: 15836828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved survival of TNF-deficient mice during the zymosan-induced multiple organ dysfunction syndrome.
    Volman TJ; Hendriks T; Verhofstad AA; Kullberg BJ; Goris RJ
    Shock; 2002 Jun; 17(6):468-72. PubMed ID: 12069182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A monoclonal antibody against tumour necrosis factor-alpha improves survival in experimental multiple organ dysfunction syndrome.
    Jansen MJ; Hendriks T; Hermsen R; Van der Meer JW; Goris RJ
    Cytokine; 1998 Nov; 10(11):904-10. PubMed ID: 9878128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of calpain inhibitor I on multiple organ failure induced by zymosan in the rat.
    Cuzzocrea S; Chatterjee PK; Mazzon E; Serraino I; Dugo L; Centorrino T; Barbera A; Ciccolo A; Fulia F; McDonald MC; Caputi AP; Thiemermann C
    Crit Care Med; 2002 Oct; 30(10):2284-94. PubMed ID: 12394957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of selective nitric oxide synthase blocker on survival, mesenteric blood flow and multiple organ failure induced by zymosan.
    Tanriverdi P; Yuksel BC; Rasa K; Guler G; Iskit AB; Guc MO; Korkmaz A
    J Surg Res; 2005 Mar; 124(1):67-73. PubMed ID: 15734481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept reduces acute tissue injury and mortality associated to zymosan-induced multiple organ dysfunction syndrome.
    Malleo G; Mazzon E; Genovese T; Di Paola R; Muià C; Caminiti R; Esposito E; Di Bella P; Cuzzocrea S
    Shock; 2008 May; 29(5):560-71. PubMed ID: 17724436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanocortins protect against multiple organ dysfunction syndrome in mice.
    Bitto A; Polito F; Altavilla D; Irrera N; Giuliani D; Ottani A; Minutoli L; Spaccapelo L; Galantucci M; Lodi R; Guzzo G; Guarini S; Squadrito F
    Br J Pharmacol; 2011 Feb; 162(4):917-28. PubMed ID: 21039420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-organ protection of ulinastatin in traumatic cardiac arrest model.
    Liu S; Xu J; Gao Y; Shen P; Xia S; Li Z; Zhang M
    World J Emerg Surg; 2018; 13():51. PubMed ID: 30459824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of tumor necrosis factor in the development of multiple organ failure in a murine model.
    Burdon D; Tiedje T; Pfeffer K; Vollmer E; Zabel P
    Crit Care Med; 2000 Jun; 28(6):1962-7. PubMed ID: 10890648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperbaric oxygen therapy reduces the toll-like receptor signaling pathway in multiple organ failures.
    Rinaldi B; Cuzzocrea S; Donniacuo M; Capuano A; Di Palma D; Imperatore F; Mazzon E; Di Paola R; Sodano L; Rossi F
    Intensive Care Med; 2011 Jul; 37(7):1110-9. PubMed ID: 21567111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of reactive oxygen species scavenger on the protective action of 100% oxygen treatment against sterile inflammation in mice.
    Hou L; Xie K; Qin M; Peng D; Ma S; Shang L; Li N; Li S; Ji G; Lu Y; Xiong L
    Shock; 2010 Jun; 33(6):646-54. PubMed ID: 19789462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Protective effects of ulinastatin against multiple organic damage after severe burn injury: experimental and clinic studies].
    Hu XH; Zhang HY; Ge YL; Chen Z; Qin FJ; Jiang HY; Chen DF; Sun YH
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(41):2889-94. PubMed ID: 16324360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GITR gene deletion and GITR-FC soluble protein administration inhibit multiple organ failure induced by zymosan.
    Galuppo M; Nocentini G; Mazzon E; Ronchetti S; Esposito E; Riccardi L; Di Paola R; Bruscoli S; Riccardi C; Cuzzocrea S
    Shock; 2011 Sep; 36(3):263-71. PubMed ID: 21654556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amelioration of the development of multiple organ dysfunction syndrome by somatostatin via suppression of intestinal mucosal mast cells.
    Tang C; Lan C; Wang C; Liu R
    Shock; 2005 May; 23(5):470-5. PubMed ID: 15834315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chlorpromazine down-regulates tumor necrosis factor-alpha and attenuates experimental multiple organ dysfunction syndrome in mice.
    Jansen MJ; Hendriks T; Knapen MF; van Kempen LC; van der Meer JW; Goris RJ
    Crit Care Med; 1998 Jul; 26(7):1244-50. PubMed ID: 9671376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tyrosine kinase inhibitor tyrphostin AG 126 reduces the multiple organ failure induced by zymosan in the rat.
    Dugo L; Chatterjee PK; Mazzon E; McDonald MC; Paola RD; Fulia F; Caputi AP; Thiemermann C; Cuzzocrea S
    Intensive Care Med; 2002 Jun; 28(6):775-88. PubMed ID: 12107686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.